I hear this every single day in my Hoffman Estates practice: “I have terrible burning pain in just my foot,” or “It’s only in my groin since the hernia surgery,” or “It’s the inside of my knee — nowhere else.” Patients have usually been told they need a spinal cord stimulator. Sometimes that’s right. Often, it’s not. When the pain is focal — confined to one specific region like a foot, a knee, a groin, or a post-surgical scar — there is a more precise tool. It’s called dorsal root ganglion (DRG) stimulation, and for the right patient, it outperforms traditional spinal cord stimulation by a meaningful margin. As a triple board-certified pain medicine specialist (ABA Anesthesiology, ABA Pain Medicine, ABIPP), I implant DRG stimulators in patients whose pain has a name, a place, and a precise anatomical address.

What DRG stimulation actually is

The dorsal root ganglion is a small cluster of sensory nerve cell bodies sitting just outside the spinal cord — one DRG for every nerve root, at every spinal level. Every sensory signal from your body — pain, touch, temperature, position sense — passes through a DRG before it ever reaches the spinal cord. That makes the DRG a precise, low-volume target. If you can put a tiny electrical lead directly on the DRG that serves the painful region, you can modulate that specific signal without affecting the rest of your nervous system. The Abbott Proclaim DRG system is currently the only FDA-approved DRG stimulator, designed specifically for focal neuropathic pain in the lower extremities (foot, knee, hip, groin) and select abdominal and pelvic distributions.

This is the most important distinction on this page: DRG is not a “smaller spinal cord stimulator.” It targets a fundamentally different anatomical structure for a fundamentally different pain pattern. Patients confuse them. Referring physicians confuse them. The two devices look superficially similar — leads, a generator, a trial period — but the patient they help is not the same patient.

Who is a candidate for DRG stimulation?

The right DRG candidate has a pain pattern I can point to on a body map without ambiguity. Strong candidates typically have:

  • Focal, neuropathic pain in one of the classic DRG-responsive distributions: the foot or ankle, the knee, the groin (post-hernia or post-orthopedic), the hip, a post-surgical scar (post-thoracotomy, post-mastectomy, post-knee replacement, post-amputation), or a specific dermatome after shingles or trauma.
  • Causalgia or Complex Regional Pain Syndrome (CRPS), Type I or Type II, in a single lower extremity. This is the indication with the strongest evidence — the ACCURATE study population.
  • Burning, electric, or stabbing quality — neuropathic features, not pure aching mechanical pain.
  • At least 6 months of pain that has failed conservative care: physical therapy, neuropathic medications (gabapentin, pregabalin, duloxetine, sometimes a topical compound), and targeted injections (sympathetic blocks for lower-extremity CRPS, nerve blocks for post-surgical neuropathic pain).
  • A psychological evaluation clearing the patient for implant — the same standard as for SCS.

I will be equally direct about who is not a good DRG candidate. DRG is the wrong answer for broad, diffuse, or bilateral pain coverage. If your pain involves both legs, your entire back, multiple non-contiguous regions, or shifts from place to place, DRG is the wrong tool. Spinal cord stimulation casts a wider net; DRG is a scalpel. If you have pain in the lower back plus both legs plus the buttocks, I’m reaching for an SCS — not a DRG. I’d rather not do a procedure than do the wrong one.

DRG is also typically reserved for lower extremity, groin, and select abdominopelvic indications under current FDA labeling. Upper extremity DRG is performed in select centers off-label but is not my routine indication.

What usually fails before DRG

The patients I see for DRG consultation have almost always done the right things first. They’ve completed physical therapy. They’ve tried gabapentin or pregabalin and either gotten partial relief or felt too sedated to function. They’ve had targeted nerve blocks — an ilioinguinal block for post-hernia groin pain, a saphenous block for medial knee pain, a sympathetic block for foot CRPS — and the blocks helped temporarily, sometimes diagnostically, but the relief never lasted. Many have had a surgical re-exploration (a hernia mesh removal, a neuroma excision) that didn’t resolve the pain. By the time DRG is on the table, the patient has exhausted the conservative ladder, and we have very strong evidence — usually a diagnostic block that gave temporary relief — that the pain is coming from a specific, identifiable neural structure. That diagnostic clarity is the strongest predictor of DRG success.

The ACCURATE study — why this device exists

You should know about one study by name. The ACCURATE trial (Deer et al., 2017) was the pivotal randomized controlled trial that compared DRG stimulation head-to-head against traditional spinal cord stimulation for CRPS and causalgia of the lower extremity [Pain 2017; PMID 28178071]. It enrolled 152 patients across 22 US centers. Both groups underwent a trial, then those who succeeded were randomized to DRG or SCS for the permanent implant.

The result was decisive. At 3 months, 81.2% of DRG patients achieved ≥50% pain relief, compared to 55.7% of SCS patients. At 12 months, the DRG advantage held — and patients reported better stability of paresthesias with body position changes (a known weakness of traditional SCS in the lower extremities). For lower-extremity CRPS and causalgia, DRG stimulation is the better-evidenced choice. Period.

That is why, when a patient walks in with CRPS in one foot or one knee — or with the burning, allodynic, color-changing presentation of causalgia after a peripheral nerve injury — DRG is my default first recommendation, not SCS.

The 7-day trial

Like SCS, every DRG patient does a trial before any permanent implant decision. The trial is performed in a 45- to 60-minute outpatient procedure under local anesthesia and light sedation. Lying face down, I place 1–4 thin DRG leads through small needles into the epidural space, then carefully advance each lead into the foramen — the bony channel where the nerve root exits the spine — and position it directly on the DRG serving the painful region. Lead placement is precise: a foot pain trial usually targets L4 or L5; a knee pain trial typically targets L3 or L4; a groin pain trial targets T12 or L1. Under live fluoroscopy I confirm position, and we test stimulation while you’re awake enough to provide feedback on coverage.

You go home with the external generator for 7 days. The success threshold is the same as SCS: ≥50% pain reduction and meaningful functional improvement. In my experience and in the literature, DRG trials for the right indication have a high pass rate — often higher than SCS trials for comparable patients — because the device is being matched to the precise anatomical target.

What the permanent implant looks like

The permanent DRG implant is similar in structure to a permanent SCS — small incisions to anchor the leads, a generator pocket usually in the upper buttock or flank — but the lead placement is more delicate because we’re working in the bony foramen rather than the wide-open epidural space. For the permanent DRG implant in my practice, I coordinate with a neurosurgeon partner for the lead-anchor and pocket-creation portions of the procedure. The same logic applies as with SCS: team-based implantation lowers complications and gets the patient through a single procedure with both expertise sets in the room.

The permanent procedure takes 75–120 minutes under monitored anesthesia care, sometimes with brief general anesthesia for the pocket creation. You go home the same day.

Recovery and return to activity

The first 24 hours are similar to any neuromodulation implant: no bending, lifting, or twisting; ice and acetaminophen for soreness at the incision sites; back-or-side sleeping with a pillow.

First week: light walking only, no driving while on sedating medications, no shower over the dressings. Weeks two to six: progressive return to normal activity, no lifting over 10 pounds, no aggressive bending or twisting. This is the lead-stabilization window — DRG leads need scar tissue to anchor them in the foramen. Six to twelve weeks: clearance for return to full activity. Patients who walk, hike, cycle, or train return to those activities incrementally. Because the DRG lead sits in the bony foramen rather than floating in the epidural space, lead migration risk has historically been lower than first-generation SCS — but the early healing period still matters.

Device programming visits happen over the first 3 to 6 months, then routine pain-medicine follow-up twice yearly.

Risks — the honest list

DRG carries the same general risk profile as SCS, with a few procedure-specific notes. Common (1–5%): lead migration (lower than SCS in published series but not zero), wound infection at the generator pocket, seroma, and dural puncture during foraminal lead placement. Rare but serious (<1%): epidural hematoma, epidural abscess, lasting nerve injury, device failure requiring revision, and — specific to DRG — temporary motor symptoms in the targeted nerve distribution if the lead position causes irritation (almost always resolves with reprogramming or repositioning). The international NACC consensus on bleeding and infection prevention applies to DRG as well [Deer et al., Neuromodulation 2017; PMID 27986601] — we screen anticoagulation, active infection, and dental work meticulously before either procedure.

Alternatives and how I decide

This is the section that matters. If you’ve been told you need a “stimulator,” the differences between the options are real and worth understanding.

DRG vs. spinal cord stimulation (SCS). This is the most common decision I make in my Hoffman Estates practice. If your pain is focal — one foot, one knee, the groin, one post-surgical scar — DRG is my default. The ACCURATE evidence is clear, and the precision of DRG matches the precision of the pain. If your pain is broad — back plus both legs, multiple regions, bilateral coverage, or axial low back pain — SCS is the right tool. (Read more about spinal cord stimulation and the four modern waveforms — HF10, BurstDR, closed-loop, traditional — on the SCS page.)

DRG vs. peripheral nerve stimulation (PNS). This is the harder decision. PNS targets the nerve itself in the periphery — for example, the ilioinguinal nerve in the groin or the occipital nerve in the back of the head. DRG targets the cell bodies just outside the spinal cord. PNS is less invasive, leaves nothing in the spinal canal, and is often the right first step for single-peripheral-nerve pain (e.g., classic occipital neuralgia, an injured saphenous nerve). I’ll typically choose DRG over PNS when the pain pattern is dermatomal (covers the whole dermatome, not just a single peripheral branch), when there’s a strong CRPS component, or when prior PNS has failed. See my peripheral nerve stimulation page for the full decision frame.

DRG vs. sympathetic blocks and CRPS-directed therapy. For active CRPS, I rarely jump straight to DRG. The pathway in my practice typically starts with a series of sympathetic blocks (lumbar sympathetic for lower extremity, stellate ganglion for upper extremity), aggressive physical therapy, neuropathic medications, and sometimes ketamine. If the patient has a sustained response, we ride that. If the blocks help temporarily but the pain returns, DRG is often the next step. Read more on the CRPS treatment page.

DRG vs. more surgery. For post-surgical neuropathic pain (post-knee replacement, post-hernia, post-amputation), additional surgery is rarely the answer and frequently makes things worse. DRG is specifically designed for this population.

When I wouldn’t choose DRG. Diffuse or bilateral pain, axial low back pain, upper-extremity pain (off-label), active infection, uncontrolled coagulopathy, severe untreated depression or active substance use, pregnancy, or a pain pattern that doesn’t have a clean anatomical home.

Insurance and prior authorization

DRG stimulation is covered by Medicare and most major commercial insurers in Illinois — but coverage is gated by documentation that establishes the focal, neuropathic nature of the pain. Successful prior authorization typically requires: ≥6 months of documented focal neuropathic pain, failure of physical therapy and neuropathic medications, at least one diagnostic block that supports the localized neural origin, a current psychological evaluation, and a clinical letter making the case for DRG specifically (rather than SCS). My office handles the prior authorization paperwork — the psych eval referral, the documentation packet, the clinical letter, and the peer-to-peer call if your insurer requests one. Once the 7-day trial succeeds, the permanent implant authorization is typically straightforward.

Frequently asked questions

How is DRG different from a spinal cord stimulator? DRG targets a specific anatomical structure (the dorsal root ganglion) that serves a single dermatome — making it precise for focal pain in one foot, knee, or scar. Traditional SCS stimulates the spinal cord broadly, which is better for diffuse or bilateral pain. They are not interchangeable.

Is DRG only for CRPS? No. CRPS and causalgia have the strongest randomized evidence (the ACCURATE trial), but DRG is widely used for post-surgical neuropathic pain (post-knee replacement, post-hernia groin pain, post-mastectomy), painful diabetic neuropathy of the foot, and other focal neuropathic syndromes in the lower extremity and groin.

Can DRG help my upper extremity pain? The FDA-approved indication is for the trunk and lower extremities. Upper-extremity DRG is performed in selected centers off-label but is not my routine indication — for upper-extremity neuropathic pain, peripheral nerve stimulation or traditional SCS is usually a better fit.

Does DRG produce a tingling sensation? Most patients on modern DRG programming report little or no paresthesia — the device works at much lower energy levels than traditional SCS, so the stimulation is typically subtle or imperceptible.

Can I get an MRI with a DRG stimulator? Yes. The current Abbott Proclaim DRG system is MRI-conditional under specific scanner protocols. You receive a device identification card to share with imaging staff.

How long does the trial take? The trial implant procedure is 45–60 minutes outpatient. You then wear the external system for 7 days. After 7 days, we measure pain reduction and functional improvement before deciding about the permanent implant.

If you’re considering DRG stimulation

If you have focal neuropathic pain — one foot, one knee, the groin, a post-surgical scar — and you’ve been told the next step is a “stimulator,” it’s worth getting a precise opinion before you commit. Spinal cord stimulators and DRG stimulators are not interchangeable, and getting the wrong one is a real cost. Call my Hoffman Estates, Illinois office at (847) 981-3630 to schedule a consultation. I’ll review your imaging, your block history, and your pain pattern with you, and — if DRG is the right answer — explain the trial in detail before anything is committed.